Evidence map›Paper›PMID 39925239›Full record

SynthesisCell transplantation

Stem Cell-Based Therapies via Different Administration Route for Stroke: A Meta-analysis of Comparative Studies.

Gabriella Jeanne Mulia, Novelia Anna, John Chung-Che Wu, Hon-Ping Ma, Yung-Hsiao Chiang, Ju-Chi Ou, Kai-Yun Chen

Abstract readMeta-AnalysisComparative Study
In one paragraph

Synthesis in Cell transplantation. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Gabriella Jeanne MuliaInternational Master Program in Medical Neuroscience, College of Medical Science and Technology, Taipei Medical University, Taipei.ORCID 0009-0006-0446-9879
Novelia AnnaDepartment of Biotechnology, Indonesia International Institute for Life Sciences, East Jakarta, Indonesia.ORCID 0009-0007-2260-2351
John Chung-Che WuDepartment of Surgery, School of Medicine, College of Medicine, Taipei Medical University, Taipei.
Hon-Ping MaGraduate Institute of Injury Prevention and Control, Taipei Medical University, Taipei.ORCID 0000-0001-7568-1451
Yung-Hsiao ChiangDepartment of Surgery, School of Medicine, College of Medicine, Taipei Medical University, Taipei.ORCID 0000-0002-8426-4016
Ju-Chi OuDepartment of Surgery, School of Medicine, College of Medicine, Taipei Medical University, Taipei.ORCID 0000-0003-3549-7283
Kai-Yun ChenInternational Master Program in Medical Neuroscience, College of Medical Science and Technology, Taipei Medical University, Taipei.ORCID 0000-0002-2941-3197

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Stroke, a neurological condition from compromised cerebral blood perfusion, remains a major global cause of mortality and disability. Conventional therapies like tissue plasminogen activator are limited by narrow therapeutic windows and potential adverse effects, highlighting the urgency for novel treatments. Stem cell-based therapies, with their neuroprotective and regenerative properties, present a promising yet highly diverse alternative. By conducting literature search and data extraction from the PubMed, Embase, and Cochrane databases, this meta-analysis assessed the clinical efficacy and safety of stem cell-based therapies administered via intravenous (IV) and non-IV routes in 17 studies with stroke patients. Primary outcomes included the National Institute of Health Stroke Scale (NIHSS), Barthel Index (BI), and modified Rankin Scale (mRS), while secondary outcomes included mortality and adverse events. Results demonstrated significant improvements in NIHSS, BI, and mRS scores, particularly in non-IV groups within 6- and 12-month follow-ups, suggesting delayed but enhanced therapeutic efficacy. Mortality was reduced in both IV and non-IV groups, indicating treatment safety. Adverse events, categorized into neurological and systemic complications, showed no significant differences between intervention and control groups, further emphasizing the safety of stem cell therapies. Non-IV routes showed more long-term benefits, potentially due to enhanced cell delivery and integration. These findings demonstrate the potential of stem cell therapies to improve functional recovery and survival in stroke patients, regardless of administration route. However, the delayed response underscores the need for extended follow-up in clinical applications. Further research is required to standardize treatment protocols, optimize cell types and doses, and address patient-specific factors to integrate stem cell therapies into routine clinical practice.

Indexed as

Stem CellsStem Cell TransplantationStrokeHumansTreatment Outcomeadverse eventBImortalitymRSNIHSSstem cellstroke

Identifiers

PMID39925239
PMCPMC11808770

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.